

Lutetium PSMA	SAS Category and State/Territory				
Application Month	None Recorded	SAS-A Total	SAS-B	SAS-B Total	Grand Total
2020				1	1
Dec				1	1
2021	28	599		44	643
Jan		39		5	44
Feb				1	46
Mar		28		7	35
Apr	8	57			57
May	1	57		1	58
Jun	2	59		2	61
Jul	12			5	61
Aug	3	46		2	48
Sep		66		5	71
Oct	1	61		5	66
Nov	1			4	40
Dec		49		7	56
2022		556		42	598
Jan				5	34
Feb		36		11	47
Mar		45		10	55
Apr		44		1	45
May		44			44
Jun				1	57
Jul		56		2	58
Aug		58			58
Sep		50		4	54
Oct		50		4	54
Nov		47		3	50
Dec		41		1	42
2023	1	629		38	667
Jan				5	55
Feb		43		11	54
Mar		73		6	79
Apr		50		1	51
May		52			52
Jun		59		4	63
Jul		47		3	50
Aug		64		1	65
Sep		56			56
Oct		46		6	52
Nov	1				53
Dec		36		1	37
2024		542		1	543
Jan		37			37
Feb		51			51
Mar		27			27
Apr		47			47
May		43			43
Jun		19			19
Jul		47		1	48
Aug		111			111
Sep		28			28
Oct		76			76
Nov		32			32
Dec		24			24
2025		93			93
Jan		20			20
Feb		14			14
Mar		10			10
Apr		11			11
May		13			13
Jun		10			10
Jul		6			6
Aug		3			3
Sep		3			3
Oct					1
Nov		2			2
Grand Total	29	2419		126	2545

Lutetium (Lu 177 Rosopatamab tetraexatan)	SAS Category and State/Territory		
Application month	SAS-A	SAS-A Total	Grand Total
2024		2	2
Nov		1	1
Dec		1	1
2025		8	8
Mar		3	3
Aug		3	3
Nov		2	2
Grand Total		10	10

Reporting Period	Number of Patients
01/01/2022 - 30/06/2022	104
01/01/2023 - 30/06/2023	105
01/01/2024 - 30/06/2024	122
01/07/2021 - 31/12/2021	111
01/07/2022 - 31/12/2022	108
01/07/2023 - 31/12/2023	165
01/07/2024 - 31/12/2024	296
Grand Total	1011